Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JV3R | ISIN: US3632252025 | Ticker-Symbol: PHPN
Tradegate
25.06.25 | 19:02
2,100 Euro
+2,94 % +0,060
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GALECTIN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GALECTIN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9502,04028.06.
1,9602,10027.06.

Aktuelle News zur GALECTIN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright26
GALECTIN THERAPEUTICS Aktie jetzt für 0€ handeln
16.06.GALECTIN THERAPEUTICS INC - 8-K, Current Report6
10.06.Galectin Therapeutics Inc.: Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension1
15.05.Galectin Therapeutics GAAP EPS of -$0.151
15.05.GALECTIN THERAPEUTICS INC - 10-Q, Quarterly Report-
12.05.Galectin Therapeutics Inc.: Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress1
12.05.GALECTIN THERAPEUTICS INC - 8-K, Current Report2
31.03.Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update266NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...
► Artikel lesen
31.03.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
31.03.GALECTIN THERAPEUTICS INC - 10-K, Annual Report-
19.03.BIOXYTRAN, INC.: Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens156In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical...
► Artikel lesen
05.03.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
18.02.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
23.01.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
13.01.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
20.12.24Galectin Therapeutics Inc.: Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH402In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices in the primary end point intent-to-treat...
► Artikel lesen
14.11.24Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update164NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that...
► Artikel lesen
13.08.24Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update118NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics...
► Artikel lesen
01.08.24Galectin Therapeutics Inc.: Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer165NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1